<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="fdb4cbbd-72e7-4933-98f6-40223f452233"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <br/> These highlights do not include all the information needed to use EPINEPHRINE INJECTION USP safely and effectively. See full prescribing information for EPINEPHRINE INJECTION USP. <br/>
      <br/> EPINEPHRINE INJECTION, USP for intravenous Infusion only<br/>
      <br/> Initial U.S. Approval: 1939</title>
   <effectiveTime value="20250318"/>
   <setId root="7499cbca-b8fe-4fc3-a318-13859ab989a7"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="078627620"/>
            <name>BPI Labs, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="078627620"/>
                        <name>BPI Labs, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54288-117" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54288-117" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="06fd9434-7f89-8119-e063-6394a90ac4d1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20231005"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54288-117" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>EPINEPHRINE</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>EPINEPHRINE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM METABISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YKH834O4BH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EPINEPHRINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YKH834O4BH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPINEPHRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54288-117-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="54288-117-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230524"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205029" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230524"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L4daaa3db-3172-4981-8e77-2a79bbbd0800">
               <id root="d798c1d8-c384-4906-b0a0-77af90d16d00"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Epinephrine is a non-selective alpha and beta adrenergic agonist indicated:</paragraph>
                        <list listType="unordered">
                           <item>To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. (1.1)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lc16c3759-06d9-414e-835f-b4b9fb165549">
                     <id root="f84f2a1a-3862-4633-aee0-b621d76d330b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Hypotension associated with Septic Shock</title>
                     <text>
                        <paragraph styleCode="Body First">Epinephrine Injection USP, 1 mg/mL is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Led99961f-1f08-4470-b735-07bbf4796f58">
               <id root="f829b43b-d3ac-436e-a41e-eda75a53b61b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20241121"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Hypotension associated with septic shock (2.2):</content>
                              <br/> o Dilute epinephrine in dextrose solution prior to infusion. <br/> o Infuse epinephrine into a large vein. <br/> o Titrate 0.05 mcg/kg/min to 2 mcg/kg/min to achieve desired blood pressure. <br/> o Wean gradually.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L3b836a39-11f7-41ff-88cb-922940bea5f7">
                     <id root="3e92905a-19c7-483d-aba8-42840bd038e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Considerations</title>
                     <text>
                        <paragraph styleCode="Body First">Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the solution is colored or cloudy, or if it contains particulate matter. Discard any unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20241121"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb4786923-9ef6-4f0d-aadf-d5dd02c019b1">
                     <id root="7da38ecc-5657-4f36-bab0-9ecb1614828b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Hypotension associated with Septic Shock</title>
                     <text>
                        <paragraph styleCode="Body First">Dilute epinephrine in 5% Dextrose Injection or 5 % Dextrose and 0.9% Sodium Chloride Injection. These dextrose containing fluids provide protection against significant loss of potency by oxidation. <content styleCode="bold">Administration in  0.9 % Sodium Chloride Injection alone is not recommended</content>. Whole blood or plasma, if indicated to increase blood volume, should be administered separately.</paragraph>
                        <paragraph>Add 1 mL (1 mg) of epinephrine from its Syringe to 1,000 mL of a 5% Dextrose containing solution. Each mL of this dilution contains 1 mcg of epinephrine.</paragraph>
                        <paragraph>Correct blood volume depletion as fully as possible before any vasopressor is administered. When, as an emergency measure, intraaortic pressures must be maintained to prevent cerebral or coronary artery ischemia, epinephrine can be administered before and concurrently with blood volume replacement.</paragraph>
                        <paragraph>Whenever possible, give infusions of epinephrine into a large vein. Avoid using a catheter tie-in technique, because the obstruction to blood flow around the tubing may cause stasis and increased local concentration of the drug. Occlusive vascular diseases (for example, atherosclerosis, arteriosclerosis, diabetic endarteritis, Buerger’s disease) are more likely to occur in the lower than in the upper extremity; therefore, avoid the veins of the leg in elderly patients or in those suffering from such disorders. There is potential for gangrene in a lower extremity when infusions of catecholamine are given in an ankle vein.</paragraph>
                        <paragraph>To provide hemodynamic support in septic shock associated hypotension in adult patients, the suggested dosing infusion rate of intravenously administered epinephrine is 0.05 mcg/kg/min to 2 mcg/kg/min, and is titrated to achieve a desired mean arterial pressure (MAP). The dosage may be adjusted periodically, such as every 10 to 15 minutes, in increments of 0.05 mcg/kg/min to 0.2 mcg/kg/min, to achieve the desired blood pressure goal.</paragraph>
                        <paragraph>Continuous epinephrine infusion is generally required over several hours or days until the patient’s hemodynamic status improves. The duration of perfusion or total cumulative dose cannot be predicted.</paragraph>
                        <paragraph> After hemodynamic stabilization, wean incrementally over time, such as by decreasing doses of epinephrine every 30 minutes over a 12- to 24-hour period.</paragraph>
                     </text>
                     <effectiveTime value="20241121"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L45e03577-c97b-49ba-b621-744eef458573">
               <id root="73fdae3b-cb09-422f-b0b7-076dfa8b6108"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph styleCode="Body First">Injection solution: 1 mg/mL epinephrine as a sterile solution in a 1 mL glass syringe, marked Epinephrine Injection USP, 1 mg/mL.</paragraph>
               </text>
               <effectiveTime value="20241121"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection solution: 1 mg/mL Syringe. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L00832034-e0a8-4ebf-96e1-bdd017d233bb">
               <id root="06fd4e9f-bc79-0d5f-e063-6294a90ad352"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20230524"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="La4b74775-4558-45ec-9136-1333dd0830b0">
               <id root="053aafcf-4df3-4f1b-a151-044ad85c9cc8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20241121"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Monitor patient for acute severe hypertension. (5.1)</item>
                           <item>Avoid extravasation into tissues, which can cause local necrosis. (5.2)</item>
                           <item>Potential for pulmonary edema, which may be fatal. (5.3)</item>
                           <item>May constrict renal blood vessels and decrease urine formation. (5.4)</item>
                           <item>May induce potentially serious cardiac arrhythmias or aggravate angina pectoris, particularly in patients with underlying heart disease. (5.5)</item>
                           <item>Presence of sulfite in this product should not deter use. (5.7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="La605413f-d2dd-4350-a520-132b0428d2f5">
                     <id root="25f90706-563f-443d-b529-b5e09d833d07"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypertension</title>
                     <text>
                        <paragraph styleCode="Body First">When Epinephrine Injection is administered intravenously, titrate the infusion while monitoring vital signs. Invasive arterial blood pressure monitoring and central venous pressure monitoring are recommended. Because of varying response to epinephrine, dangerously high blood pressure may occur [ <content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20241121"/>
                  </section>
               </component>
               <component>
                  <section ID="L1f290d91-66e8-4474-aa79-217451d748b5">
                     <id root="06fd4e9f-bc7c-0d5f-e063-6294a90ad352"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Extravasation and Tissue Necrosis with Intravenous Infusion</title>
                     <text>
                        <paragraph styleCode="Body First">When Epinephrine Injection is administered intravenously, the infusion site should be checked frequently for free flow. Avoid extravasation of epinephrine into the tissues, to prevent local necrosis. Blanching along the course of the infused vein, sometimes without obvious extravasation, may be attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage. This also may progress on rare occasions to superficial slough. Hence, if blanching occurs, consider changing the infusion site at intervals to allow the effects of local vasoconstriction to subside.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Antidote for Extravasation Ischemia:</content>To prevent sloughing and necrosis in areas in which extravasation has taken place, infiltrate the area with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of phentolamine, an adrenergic blocking agent. Use a syringe with a fine hypodermic needle, with the solution being infiltrated liberally throughout the area, which is easily identified by its cold, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.

 </paragraph>
                     </text>
                     <effectiveTime value="20230524"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf476d191-fb3f-4092-8ae2-d902c075e60d">
                     <id root="06fd4e9f-bc7d-0d5f-e063-6294a90ad352"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Pulmonary Edema</title>
                     <text>
                        <paragraph>When Epinephrine Injection is administered intravenously, there is risk of pulmonary edema because of the peripheral constriction and cardiac stimulation produced. Treatment of pulmonary edema consists of a rapidly acting alpha-adrenergic blocking drug (such as phentolamine mesylate) and respiratory support.</paragraph>
                     </text>
                     <effectiveTime value="20230524"/>
                  </section>
               </component>
               <component>
                  <section ID="L19f56e7a-bf22-41bc-adc2-c7fd49ed7904">
                     <id root="06fd4e9f-bc7e-0d5f-e063-6294a90ad352"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Renal Impairment</title>
                     <text>
                        <paragraph styleCode="Body First">Intravenously administered epinephrine initially may produce constriction of renal blood vessels and decrease urine formation.</paragraph>
                     </text>
                     <effectiveTime value="20230524"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf82dd4c2-ac24-454b-a6d0-56bbfb9c60f0">
                     <id root="7e4fa58b-55b4-4280-a0e1-68605e170f3b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Cardiac Arrhythmias and Ischemia</title>
                     <text>
                        <paragraph styleCode="Body First">Epinephrine may induce cardiac arrhythmias and angina pectoris in patients, especially patients suffering from coronary artery disease, organic heart disease, cerebrovascular disease, hypertension, or patients who are receiving drugs that sensitize the myocardium [see <content styleCode="italics">Adverse Reactions (6) </content>and <content styleCode="italics">Drug Interactions (7)</content>]. Treatment of arrhythmias consists of administration of a beta-adrenergic blocking drug (such as propranolol).</paragraph>
                     </text>
                     <effectiveTime value="20241121"/>
                  </section>
               </component>
               <component>
                  <section ID="L5e6e6cde-6353-4741-a8eb-f6fad08ede58">
                     <id root="06fd4e9f-bc80-0d5f-e063-6294a90ad352"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Other Disease Interactions</title>
                     <text>
                        <paragraph styleCode="Body First">Epinephrine should be administered with caution to patients with hyperthyroidism, Parkinson’s disease, diabetes mellitus, pheochromocytoma, elderly individuals, and pregnant women. Patients with Parkinson’s disease may experience psychomotor agitation or notice a temporary worsening of symptoms. Diabetic patients may experience transient increases in blood sugar. Despite these concerns, the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation.</paragraph>
                     </text>
                     <effectiveTime value="20230524"/>
                  </section>
               </component>
               <component>
                  <section ID="L3d7e5771-0b6b-48be-a202-f7b3fae30a84">
                     <id root="06fd4e9f-bc81-0d5f-e063-6294a90ad352"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Allergic Reactions Associated with Sulfite</title>
                     <text>
                        <paragraph styleCode="Body First">Epinephrine is the preferred treatment for serious allergic or other emergency situations even though this product contains sodium metabisulfite, a sulfite that may in other products cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of sulfite(s) in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations.</paragraph>
                     </text>
                     <effectiveTime value="20230524"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L0e01b462-5c69-43f4-b4c8-8cee2a577bfd">
               <id root="38046996-6c3e-4fa8-b593-abaf95a899ac"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text/>
               <effectiveTime value="20241121"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions to systemically administered epinephrine are headache; anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; peripheral coldness; nausea/vomiting; and/or respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred. </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact BPI Labs, LLC at (727) 471-0850 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="underline">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lf74283b0-7558-4c07-8e44-5dc35046ffd0">
                     <id root="5e04d407-52ca-4f1e-a4d0-7b95014b0187"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph styleCode="Body First">The following adverse reactions associated with the infusion of epinephrine were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Cardiovascular disorders</content>: tachycardia, supraventricular tachycardia, ventricular arrhythmias, myocardial ischemia, myocardial infarction, limb ischemia, pulmonary edema</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Gastrointestinal disorders</content>: Nausea, vomiting</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">General disorders and administrative site conditions</content>: Chest pain, extravasation,</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Metabolic</content>: hypoglycemia, hyperglycemia, insulin resistance, hypokalemia, lactic acidosis</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Nervous system disorders</content>: Headache, nervousness, paresthesia, tremor, stroke, central nervous system bleeding</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Psychiatric disorders</content>: Excitability</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Renal disorders</content>: Renal insufficiency</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Respiratory</content>: Pulmonary edema, rales</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Skin and subcutaneous tissue disorders</content>: Diaphoresis, pallor, piloerection, skin blanching, skin necrosis with extravasation</paragraph>
                     </text>
                     <effectiveTime value="20241121"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L0a327113-91eb-4547-aebc-f52c943f166d">
               <id root="d690e7b3-ff83-4e82-987b-96c72291ddf5"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Drugs antagonizing pressor effects of epinephrine</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>
                  </paragraph>
                  <list listType="unordered">
                     <item>α-blockers, such as phentolamine</item>
                     <item>Vasodilators, such as nitrates</item>
                     <item>Diuretics</item>
                     <item>Antihypertensives</item>
                     <item>Ergot alkaloids</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Drugs potentiating pressor effects of epinephrine</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Sympathomimetics</item>
                     <item>β-blockers, such as propranolol</item>
                     <item>Tricyclic anti-depressants</item>
                     <item>Monoamine oxidase (MAO) inhibitors</item>
                     <item>Catechol-O-methyl transferase (COMT) inhibitors, such as entacapone</item>
                     <item>Clonidine</item>
                     <item>Doxapram</item>
                     <item>Oxytocin</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Drugs potentiating arrhythmogenic effects of epinephrine</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>
                  </paragraph>
                  <paragraph>Patients who are concomitantly receiving any of the following drugs should be observed carefully for the development of cardiac arrhythmias [see <content styleCode="italics"> Warnings and Precautions (5.5) </content>and <content styleCode="italics"> Adverse Reactions (6)</content>].</paragraph>
                  <list listType="unordered">
                     <item>β-blockers, such as propranolol</item>
                     <item>Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane</item>
                     <item>Antihistamines</item>
                     <item>Thyroid hormones</item>
                     <item>Diuretics</item>
                     <item>Cardiac glycosides, such as digitalis glycosides</item>
                     <item>Quinidine</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Drugs potentiating hypokalemic effects of epinephrine</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Potassium depleting diuretics</item>
                     <item>Corticosteroids</item>
                     <item>Theophylline</item>
                  </list>
                  <paragraph>Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure.</paragraph>
                  <paragraph>Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. </paragraph>
               </text>
               <effectiveTime value="20241121"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7)</item>
                           <item>Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7)</item>
                           <item>Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides. Observe for development of cardiac arrhythmias. (7)</item>
                           <item>Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine. (7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L01a73a79-1fe8-449d-8674-ad6dad5a3a08">
               <id root="2dd6d972-b895-440b-90a0-21e8049e3fae"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20241105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pregnancy: May cause fetal harm (8.1)</item>
                           <item>Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally. (8.1, 8.5) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Ldd7e939f-2ce2-4121-8ae9-d10641f3fffb">
                     <id root="c58a3d34-5a71-4e13-a985-9397f7d3067d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph styleCode="Body First">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph styleCode="Body">Prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, does not identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, there are risks to the mother and fetus associated with epinephrine use during labor or delivery (see <content styleCode="italics">Clinical Considerations</content>). In animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis, resulted in adverse developmental effects (including gastroschisis, embryonic lethality, and delayed skeletal ossification) at doses approximately 2 times the maximum recommended daily intramuscular, subcutaneous, or intravenous dose (see <content styleCode="italics">Data</content>).</paragraph>
                        <paragraph styleCode="Body">The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph styleCode="Body">Hypotension associated with septic shock is a medical emergency in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic shock may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of epinephrine on the fetus.</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="italics">Labor or Delivery</content>
                        </paragraph>
                        <paragraph styleCode="Body">Epinephrine usually inhibits spontaneous or oxytocin-induced contractions of the pregnant human uterus and may delay the second stage of labor. Avoid epinephrine during the second stage of labor. In dosage sufficient to reduce uterine contractions, the drug may cause a prolonged period of uterine atony with hemorrhage. Avoid epinephrine in obstetrics when maternal blood pressure exceeds 130/80 mmHg.</paragraph>
                        <paragraph styleCode="Body">Although epinephrine may improve maternal hypotension associated with septic shock and anaphylaxis, it may result in uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia.</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph styleCode="Body">In an embryofetal development study with pregnant rabbits dosed during the period of organogenesis (on days 3 to 5, 6 to 7, or 7 to 9 of gestation), epinephrine caused teratogenic effects (including gastroschisis) at doses approximately 15 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m <sup>2 </sup>basis at a maternal subcutaneous dose of 1.2 mg/kg/day for 2 to 3 days). Animals treated on days 6 to 7 had decreased number of implantations.</paragraph>
                        <paragraph styleCode="Body">In an embryofetal development study, pregnant mice were administered epinephrine (0.1 to 10 mg/kg/day) on Gestation Days 6 to 15. Teratogenic effects, embryonic lethality, and delays in skeletal ossification were observed at approximately 3 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m <sup>2 </sup>basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m <sup>2 </sup>basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days).</paragraph>
                        <paragraph styleCode="Body">In an embryofetal development study with pregnant hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine produced reductions in litter size and delayed skeletal ossification at doses approximately 2 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m <sup>2  </sup>basis at a maternal subcutaneous dose of 0.5 mg/kg/day).</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
               <component>
                  <section ID="L17936237-8fad-43e4-857a-d678d51e67bd">
                     <id root="02ca4abb-9056-4824-937c-4c346a91a03c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph styleCode="Body First">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph styleCode="Body">There is no information regarding the presence of epinephrine in human milk or the effects of epinephrine on the breastfed infant or on milk production. However, due to its poor oral bioavailability and short half-life, epinephrine exposure is expected to be very low in the breastfed infant.</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
               <component>
                  <section ID="L9ade5a14-e249-45b1-9dd7-96ffabf5e249">
                     <id root="8bfe1622-3164-4afa-bb49-2ec6834b3376"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph styleCode="Body First">Safety and effectiveness of epinephrine in pediatric patients with septic shock have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
               <component>
                  <section ID="L745bfe51-a0a6-4157-941a-968332b7aa56">
                     <id root="8b9fe51e-83b3-4f8f-9bb8-a61e6035d52d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph styleCode="Body First">Clinical studies of epinephrine for the treatment of hypotension associated with septic shock did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lff69e50e-f9a0-4607-a637-818aabe7954f">
               <id root="3f72ec8d-2f73-4db0-9965-9eb867124ba4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph styleCode="Body First">Overdosage of epinephrine may produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients. Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation. Epinephrine overdosage may also cause transient bradycardia followed by tachycardia and these may be accompanied by potentially fatal cardiac arrhythmias. Premature ventricular contractions may appear within one minute after injection and may be followed by multifocal ventricular tachycardia (prefibrillation rhythm). Subsidence of the ventricular effects may be followed by atrial tachycardia and occasionally by atrioventricular block. Myocardial ischemia and infarction, cardiomyopathy, extreme pallor and coldness of the skin, metabolic acidosis due to elevated blood lactic acid levels, and renal insufficiency and failure have also been reported.</paragraph>
                  <paragraph styleCode="Body">Epinephrine is rapidly inactivated in the body and treatment following overdose is primarily supportive. Treatment of pulmonary edema consists of a rapidly acting alpha-adrenergic blocking drug (such as phentolamine mesylate) and respiratory support. Treatment of arrhythmias consists of administration of a beta-adrenergic blocking drug (such as propranolol). If necessary, pressor effects may be counteracted by rapidly acting vasodilators (such as nitrites) or alpha-adrenergic blocking drugs. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug. </paragraph>
               </text>
               <effectiveTime value="20241105"/>
            </section>
         </component>
         <component>
            <section ID="La89375af-e5d4-49e7-85d6-4ff7fa3e76d1">
               <id root="777c548c-fd18-489e-bb50-6e9c05cc7876"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph styleCode="Body First">Epinephrine Injection USP is a clear, colorless, sterile solution containing 1 mg/mL epinephrine, packaged as a 1 mL solution in a 1 mL single dose syringe. Each mL of Epinephrine Injection, USP solution contains 1 mg epinephrine, 8.6 mg sodium chloride, 1.5 mg sodium metabisulfite, q.s hydrochloric acid as a dissolution and pH adjustment, and water for injection. The pH range is 2.2-5.0.</paragraph>
                  <paragraph>Solution must be diluted prior to intravenous use.</paragraph>
                  <paragraph>Epinephrine is a sympathomimetic catecholamine. The chemical name of epinephrine is: 1,2- Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]-, or (-)-3,4-Dihydroxy- <content styleCode="bold">α</content>-[2- (methylamino)ethyl]benzyl alcohol. The chemical structure of epinephrine is:</paragraph>
                  <paragraph styleCode="Body">
                     <renderMultiMedia referencedObject="L1991bb7d-2dbb-4776-a1cb-8c7c42899aee"/>
                  </paragraph>
                  <paragraph styleCode="Body"/>
                  <paragraph styleCode="Body">The molecular weight of epinephrine is 183.2.</paragraph>
                  <paragraph styleCode="Body">Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="L1991bb7d-2dbb-4776-a1cb-8c7c42899aee">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="La476de4a-e616-46a8-ae3d-5c5479d2380f">
               <id root="09d6d00a-c65c-4c55-a871-2881a77ddfec"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20241105"/>
               <component>
                  <section ID="L6e32b1ea-8a9a-4b49-ba83-2db4fff2c20c">
                     <id root="61a916cf-4ad1-4c1f-a0c5-19f7e01ee901"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph styleCode="Body First">Epinephrine acts on both alpha (α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction. </paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
               <component>
                  <section ID="L4bd9502f-5f5d-46e3-9883-a77036d644dc">
                     <id root="ea7ded87-6eb2-429b-bad6-ec2662b86f4f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph styleCode="Body First">
                           <content styleCode="underline">Intravenous use for hypotension associated with septic shock</content>
                        </paragraph>
                        <paragraph styleCode="Body">Following intravenous administration of epinephrine, increases in systolic blood pressure and heart rate are observed. Decreases in systemic vascular resistance and diastolic blood pressure are observed at low doses of epinephrine because of β <sub>2</sub>-mediated vasodilation, but are overtaken by α <sub>1</sub>-mediated peripheral vasoconstriction at higher doses leading to increase in diastolic blood pressure. The onset of blood pressure increase following an intravenous dose of epinephrine is &lt; 5 minutes and the time to offset blood pressure response occurs within 20 min. Most vascular beds are constricted including renal, splanchnic, mucosal and skin.</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
               <component>
                  <section ID="Lfbfd641e-c8ca-44a3-b652-c551387dc98c">
                     <id root="89c90e3e-bcd5-4f5c-969f-b02cd24179b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph styleCode="Body First">When administered parenterally, epinephrine has a rapid onset and short duration of action.</paragraph>
                        <paragraph styleCode="Body">Following intravenous injection, epinephrine is rapidly cleared from the plasma with an effective half-life of &lt; 5 min. A pharmacokinetic steady state following continuous intravenous infusion is achieved within 10-15 min. In patients with septic shock, epinephrine displays dose-proportional pharmacokinetics in the infusion dose range of 0.03 to 1.7 mcg/kg/min.</paragraph>
                        <paragraph>Epinephrine is extensively metabolized with only a small amount excreted unchanged.</paragraph>
                        <paragraph styleCode="Body">Epinephrine is rapidly degraded to vanillylmandelic acid, an inactive metabolite, by monoamine oxidase and catechol-O-methyltransferase that are abundantly expressed in the liver, kidneys and other extraneuronal tissues. The tissues with the highest contribution to removal of circulating exogenous epinephrine are the liver (32%), kidneys (25%), skeletal muscle (20%), and mesenteric organs (12%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Special Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Elderly</content>
                        </paragraph>
                        <paragraph>In a pharmacokinetic study of 45-minute epinephrine infusions given to healthy men aged 20 to 25 years and healthy men aged 60 to 65 years, the mean plasma metabolic clearance rate of epinephrine at steady state was greater among the older men (144.8 versus 78 mL/kg/min for a 14.3 ng/kg/min infusion).</paragraph>
                        <paragraph styleCode="Body">
                           <content styleCode="italics">Body Weight</content>
                        </paragraph>
                        <paragraph styleCode="Body">Body weight has been found to influence epinephrine pharmacokinetics. Higher body weight was associated with a higher plasma epinephrine clearance and a lower concentration plateau.</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lbe17d182-9326-4987-8c5d-e26f8a8d48ad">
               <id root="83c0f261-12e1-42e1-b733-6c8a80d53d6d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20241105"/>
               <component>
                  <section ID="L6af475c2-7165-4153-8389-76f423b5fbab">
                     <id root="dab64ed9-0166-4027-9fdc-6aba22bf2e6a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph styleCode="Body First">Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted.</paragraph>
                        <paragraph styleCode="Body">Epinephrine and other catecholamines have been shown to have mutagenic potential <content styleCode="italics">in vitro</content>. Epinephrine was positive in the <content styleCode="italics">Salmonella </content>bacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the <content styleCode="italics">in vivo</content>micronucleus assay. Epinephrine is an oxidative mutagen based on the <content styleCode="italics">E. coli</content>WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine under the conditions noted under the Indications and Usage.</paragraph>
                        <paragraph styleCode="Body">The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (15-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9. </paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
               <component>
                  <section ID="L98265223-dea8-4edc-a1a4-460e70101482">
                     <id root="cccf4cf8-56d1-45fb-922c-31099dede708"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Epinephrine was associated with metabolic effects, decreased mesentery, coronary and renal conductance in a sheep model of septic shock. Data from hemolysis study have shown that epinephrine at 1:1000 dilution is non-hemolytic. Epinephrine infusion significantly increased the MAP (69 vs. 86 mmHg) and cardiac output (6.4 vs. 7.1 L/min) and decreased renal blood flow (330 vs. 247 mL/min). </paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L10667f96-93a8-4037-9873-65de9289c0b2">
               <id root="016a2480-bb7f-4dcd-bfcf-d87a1ebc2d1b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text/>
               <effectiveTime value="20241105"/>
               <component>
                  <section ID="L4cf60c04-d2a6-46e7-816a-63ea174eb191">
                     <id root="5fb775fd-28fc-4154-8c69-79c8a12ec4b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Hypotension associated with Septic Shock</title>
                     <text>
                        <paragraph styleCode="Body First">Fourteen clinical studies from the literature documented that epinephrine increases the mean arterial pressure (MAP) in patients with hypotension associated with septic shock.</paragraph>
                     </text>
                     <effectiveTime value="20241105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lb553c90f-2b13-45b2-b5a9-168797599eb0">
               <id root="5d187274-03b2-4a8d-a2bb-65458f08e7d9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Epinephrine 1 mg/mL Injection is a clear, colorless solution available as follows :</paragraph>
                  <paragraph/>
                  <paragraph>      NDC 54288-117-10                              10 Single-Dose Prefilled Syringes Containing 1 mL</paragraph>
                  <paragraph/>
                  <paragraph>Epinephrine is light sensitive. Protect from light until ready to use.</paragraph>
                  <paragraph/>
                  <paragraph>Do not refrigerate. Protect from freezing.</paragraph>
                  <paragraph/>
                  <paragraph>Store at room temperature, between 20°C to 25°C (68°F to 77°F). (See USP Controlled Room Temperature.) Protect from alkalis and oxidizing agents.</paragraph>
                  <paragraph/>
                  <paragraph>Revised: December 2024</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/> BPI Labs LLC <br/> 12393 Belcher Rd S, Suite 450, <br/> Largo, FL 33773</paragraph>
                  <paragraph/>
                  <paragraph>LI11I <br/>R-2412</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="L50338bce-235a-41e5-83a5-eb1adcae0313">
               <id root="4cf21b51-d52e-487a-ae6b-1978e85b8c42"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Label</content>
                     <br/>
                     <content styleCode="bold">Epinephrine Injection, USP 1 mg/mL</content>
                     <br/>
                     <content styleCode="bold">NDC 54288-117-01</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Laaf56589-9ac4-4c7a-aa94-279baff17c65"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Carton</content>
                     <br/>
                     <content styleCode="bold">Epinephrine Injection, USP 1 mg/mL</content>
                     <br/>
                     <content styleCode="bold">NDC 54288-117-10</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L47f48d52-5a7b-4a0b-9e74-2c71941256f0"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="Laaf56589-9ac4-4c7a-aa94-279baff17c65">
                     <text>syringe-label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epinephrine-1ml-mg-syringe-label-r2412.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L47f48d52-5a7b-4a0b-9e74-2c71941256f0">
                     <text>carton-label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epinephrine-1ml-mg-syringe-10pk-carton-r2412.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>